Rare Disease Therapeutics · Cell & Gene Therapy
Sarepta news and milestones
Sarepta: 16 headlines on record, 8 headlines in the last 90 days. Its story counts 1 milestone.
Data updated Nov 18, 2026 · Back to the company report
16Headlines
8In 90 days
1Milestones
Headlines
Oct 22026
News · BioSpace
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented…
Oct 12026
Sep 302026
News · Sarepta Therapeutics stock falls 1.28 percent as DMD data land
Sarepta Therapeutics stock posted Q2 revenue of USD 401.25 million and EPS of USD 0.64 on August 5, 2026. ELEVIDYS data covered older patients at the September 30 congress.
Sep 302026
Sep 302026
Sep 262026
News · YahooFinance
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta ag…
Sep 232026
News · streetinsider.com
Sources: the outlets named on each headline, each story once
Milestones
Each milestone is dated by its source: registers, filings, the press
How to cite
Sarepta, News. Alion, Nov 18, 2026. https://alion.io/company/sarepta/news
